title: B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial.
abstract: BACKGROUND
  B-type natriuretic peptide (BNP) is used to diagnose heart failure, but the effects of using the test on all dyspneic patients is uncertain.
  
  
  OBJECTIVE
  To assess whether BNP testing alters clinical outcomes and health services use of acutely dyspneic patients.
  
  
  METHODS
  Randomized, single-blind study. Patients were assigned to a treatment group through randomized numbers in a sealed envelope. Patients were blinded to the intervention, but clinicians and those who assessed trial outcomes were not.
  
  
  METHODS
  2 Australian teaching hospital emergency departments.
  
  
  METHODS
  612 consecutive patients who presented with acute severe dyspnea from August 2005 to March 2007.
  
  
  METHODS
  BNP testing (n = 306) or no testing (n = 306).
  
  
  METHODS
  Admission rates, length of stay, and emergency department medications (primary outcomes); mortality and readmission rates (secondary outcomes).
  
  
  RESULTS
  There were no between-group differences in hospital admission rates (85.6% [BNP group] vs. 86.6% [control group]; difference, -1.0 percentage point [95% CI, -6.5 to 4.5 percentage points]; P = 0.73), length of admission (median, 4.4 days [interquartile range, 2 to 9 days] vs. 5.0 days [interquartile range, 2 to 9 days]; P = 0.94), or management of patients in the emergency department. Test discrimination was good (area under the receiver-operating characteristic curve, 0.87 [CI, 0.83 to 0.91]). Adverse events were not measured.
  
  
  CONCLUSIONS
  Most patients were very short of breath and required hospitalization; the findings might not apply for evaluating patients with milder degrees of breathlessness.
  
  
  CONCLUSIONS
  Measurement of BNP in all emergency department patients with severe shortness of breath had no apparent effects on clinical outcomes or use of health services. The findings do not support routine use of BNP testing in all severely dyspneic patients in the emergency department.
  
  
  BACKGROUND
  Janssen-Cilag.
authors.affiliation: Alfred Health, Prahran, and Royal Melbourne Hospital, Parkville, Victoria, Australia. schneiderh@alfred.org.au
authors.forename: Hans-Gerhard
authors.initials: HG
authors.lastname: Schneider
authors.forename: Louisa
authors.initials: L
authors.lastname: Lam
authors.forename: Amaali
authors.initials: A
authors.lastname: Lokuge
authors.forename: Henry
authors.initials: H
authors.lastname: Krum
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Naughton
authors.forename: Pieter
authors.initials: P
authors.lastname: De Villiers Smit
authors.forename: Adam
authors.initials: A
authors.lastname: Bystrzycki
authors.forename: David
authors.initials: D
authors.lastname: Eccleston
authors.forename: Jacob
authors.initials: J
authors.lastname: Federman
authors.forename: Genevieve
authors.initials: G
authors.lastname: Flannery
authors.forename: Peter
authors.initials: P
authors.lastname: Cameron
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia; D004417:Dyspnea / Q000209:etiology*; D004636:Emergency Service, Hospital / Q000592:standards*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D006785:Hospitals, University / Q000592:standards; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D017063:Outcome Assessment, Health Care; D010359:Patient Readmission; D016037:Single-Blind Method
chemical_list: D020097:Natriuretic Peptide, Brain